FDA authorizations extend clinical AI into new specialties and LLMs

Organizations

Updates

1. Sep 11

   The FDA granted Queen of Hearts the first De Novo for AI-ECG STEMI detection (7.9% false cath-lab activations versus 41.8% without) and codified a Class II type for cardiovascular ML notification software, while a three-country RCT found GPT-4o lifted physician performance by 7.2 to 18.0 points.

   FDA authorizes Queen of Hearts AI-ECG · FDA classifies cardiovascular ML notification software · GPT-4o lifts physician performance in three countries

2. Jul 31

   The FDA granted a De Novo for Caristo's CaRi-Heart, the first US-authorized coronary-inflammation measure from routine CT, and cleared DeepHealth's breast-ultrasound AI, ThinkSono's DVT scan guidance, and Implicity's monitor-alert filter, which cuts false positives up to 76%.

   FDA authorizes Caristo's CaRi-Heart · FDA clears DeepHealth breast ultrasound AI · FDA clears ThinkSono Guidance for DVT scans · FDA clears Implicity's ILR ECG Analyzer

3. Jul 17

   The FDA created a first-in-class De Novo category for Syncron-E's ventilator-waveform AI and cleared RadOncAI for head-and-neck radiation dose planning, validated on 900+ patients, and Universal Brain's EEG system for objective psychiatric assessment.

   FDA authorizes Autonomous Healthcare's Syncron-E · FDA clears InformAI's RadOncAI · FDA clears Universal Brain's EEG brain-function system

4. Jun 26New

   The FDA cleared Pathway Labs' EchoNext, the first multicondition cardiac AI, which flags six structural heart diseases from standard ECGs and ships through OpenEvidence, and UpDoc, the first cleared device built on patient-facing LLMs; DeepHealth's new clearance reads cardiovascular risk from routine mammograms.

   FDA clears Pathway Labs' EchoNext · FDA clears UpDoc's patient-facing LLM platform · FDA clears two DeepHealth breast-imaging tools

Predictions

1. Dec 2026

   Clearances shift from single-condition imaging toward multicondition and LLM-based patient-facing agents, with clinician platforms and EHRs as the distribution channel and reimbursement such as Medicare AI-ECG codes accelerating adoption. Jun 26

2. Jan 2027

   The FDA's willingness to create new categories via De Novo accelerates AI into critical care and psychiatry, and capital keeps flowing into AI drug and antibody design as clinical validation deepens. Jul 17

3. Jan 2027

   The FDA's willingness to open De Novo categories and clear point-of-care and manufacturer-agnostic tools accelerates AI into cardiology, imaging, and remote monitoring, with reimbursement pathways such as CPT codes as the next contested frontier. Jul 31

4. Mar 2027

   De Novo authorizations that establish new device classes, paired with prospective RCT evidence, become the gating steps for high-acuity clinical AI, intensifying scrutiny of tools cleared without outcome data. Sep 11